Novartis AG
NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
$160.79−0.31 (-0.19%)
Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –
Novartis Kisqali by Quarter
Kisqali — Total Prescription (TRx) Market Share in Metastatic Breast Cancer (mBC) in Top 10 Ex-US Markets (%)
Novartis Kisqali: 47.0% in Q3 2026, up 8.0 pts from a year earlier.
Latest, Q3 2026
47.0%
Period ended Sep 30, 2026
Change on a year earlier
+8.0 pts
39.0% in Q3 2025
History
7 quarters
Since Q1 2025
Sources
7
Documents cited below
Where the Q3 2026 figure comes from
“| DE eBC NBRx2 | Kisqali | Competitor 1 | Competitor 2 | and TRx (47%)4”
Source: Novartis Official IR / Sustainability Report — q3-2026-investor-presentation.pdf ↗
Reported in Quarterly Investor Presentations.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Kisqali — Total Prescription (TRx) Market Share in Metastatic Breast Cancer (mBC) in Top 10 Ex-US Markets (%) | Year on year | Source |
|---|---|---|---|---|
| Q3 2026 | Sep 30, 2026 | 47.0% | +8.0 pts | Novartis Official IR / Sustainability Report — q3-2026-investor-presentation.pdf ↗ |
| Q2 2026 | Jun 30, 2026 | 46.0% | +8.0 pts | Novartis Official IR / Sustainability Report — q2-2026-investor-presentation.pdf ↗ |
| Q1 2026 | Mar 31, 2026 | 39.0% | +4.0 pts | Novartis Official IR / Sustainability Report — q1-2026-investor-presentation.pdf ↗ |
| Q4 2025 | Dec 31, 2025 | 39.0% | – | Novartis Official IR / Sustainability Report — q4-2025-investor-presentation.pdf ↗ |
| Q3 2025 | Sep 30, 2025 | 39.0% | – | Novartis Official IR / Sustainability Report — q3-2025-investor-presentation.pdf ↗ |
| Q2 2025 | Jun 30, 2025 | 38.0% | – | Novartis Official IR / Sustainability Report — q2-2025-investor-presentation.pdf ↗ |
| Q1 2025 | Mar 31, 2025 | 35.0% | – | Novartis Official IR / Sustainability Report — q1-2025-investor-presentation.pdf ↗ |
Cite this data
StockData. (2026). Novartis Kisqali (%), quarterly Q1 2025–Q3 2026 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/rx-kisqali-exus-mbc-trx-pct
See every metric in the Novartis KPI table. Data updated Nov 2, 2026.